About Ajanta Pharma Limited
Ajanta Pharma Limited (AJANTPHARM) is an Indian multinational specialty pharmaceutical company founded in 1973 and headquartered in Mumbai, India. It develops, manufactures, and markets a wide range of quality pharmaceutical products, with a strong focus on branded generics in India and over 30 countries across Asia, Africa, and other emerging markets, as well as generic drugs in the United States market.
The company’s product portfolio spans multiple therapeutic areas, including cardiology, dermatology, ophthalmology, and pain management, and is known for first-to-market and differentiated formulations. It operates seven state-of-the-art manufacturing facilities in India, some of which have US FDA and WHO approvals, and maintains a robust R&D infrastructure with hundreds of scientists working on innovative formulations.
Ajanta Pharma’s mission is to serve global healthcare needs through empathy, innovation, and technology, aiming to deliver cost-effective and patient-centric medicines worldwide.
Board Meeting Outcome
Approved financial results of Q3 & 9 months FY 2026. The Board of Directors approved and took on record the unaudited financial results (consolidated and standalone) for the quarter and nine months ended 31 Dec 2025.
Q3 FY 2026 Performance (vs Q3 FY 2025)
Revenue from operations was ₹1,375 crore, up 20%. EBITDA was ₹382 crore, up 19% with 28% margin. Profit After Tax (PAT) was ₹274 crore, up 18%
Nine Months FY 2026 Performance (vs 9M FY 2025)
Revenue from operations was ₹4,031 crore, up 16%. EBITDA was ₹1,061 crore, up 10% (margin 26%). PAT was ₹789 crore, up 14%. ROCE was 34% and RONW was 26%.
Segment-wise Growth
Branded Generics (India, Asia & Africa) had growth in most markets, with strong performance in India and Africa. US Generics had significant growth with revenues up 52% for the quarter and 46% over 9M.
India Market Performance
Ajanta outpaced the Indian Pharmaceutical Market (IPM) with higher volume growth and new launches, especially in therapy areas like ophthalmology, dermatology, cardiology, and pain management.
Regulatory & R&D Status
Multiple ANDAs filed, several approvals received, and products launched in the US market. Ongoing R&D investment noted as part of long-term growth strategy.
Summary In short, Ajanta Pharma reported strong quarterly and nine-month growth in revenue and profit, with notable expansion in international markets and a robust pipeline of products under development/approval.